Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Faron Pharmaceuticals Ltd | Company announcement | June 03, 2025 at 14:00:00 EEST
Registration of New Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m. EEST 3 June 2025 regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.
Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced earlier today on 3 June 2025, approved the exercise of 352,989 Special Rights entitling to 352,989 new Shares, for an aggregate subscription price of EUR 907,499.42. Last week, on 27 May 2025, the Company announced that that the Board of Directors of Faron (the “Board”) had resolved to issue 5,000,000 treasury shares to the Company itself without consideration to prepare for any future conversions of the First Tranche Bond.
In total 5,352,989 new shares in the Company have today on 3 June 2025 been registered in the Finnish Trade Register. The shares rank pari passu in all respects with the existing shares of the Company. Following the issuance, the aggregate number of ordinary shares in the Company is 116,954,597. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company continues to have 5,000,000 shares in treasury and therefore, the total number of voting rights in Faron is 111,954,597 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.
Trading in the new shares is expected to commence on First North and AIM on or around 4 June 2025.
For more information, please contact:
| IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen | +358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi |
| FINN Partners, US (Media) Alyssa Paldo | +1 847 791-8085 alyssa.paldo@finnpartners.com |
| Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä | +358 (0)40 555 4727 +358 (0)50 553 8990 |
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.